Retatrutide, a innovative dual-acting glucose-dependent incretin agent, represents a significant leap in peptide medicines for the handling of type 2 sugar disorders and, increasingly, obesity. Unlike many existing medicinal interventions, retatrutide combines the actions of a GLP-1 receptor stimulant and a GIP receptor activator, offering a more c